Abstract:Abstract Background Porcine circovirus type 2 (PCV2) is the causative agent of postweaning multisystemic wasting syndrome, and is associated with a number of other diseases. PCV2 is widely distributed in most developed swine industries, and is a severe economic burden. With an eye to developing an effective, safe, and convenient vaccine against PCV2-associated diseases, we have constructed a recombinant Bacillus subtilis strain ( B. subtilis -Cap) that expresses the PCV2 capsid protein (Cap). Methods Electroporation of a plasmid shuttle vector encoding the PCV2 Cap sequence was use to transform Bacillus subtilis . Flow cytometry was used to evaluate in vitro bone marrow derived dendritic cell (BM-DC) maturation and T cell proliferation induced by B. subtilis -Cap. Orally inoculated piglets were used for in vivo experiments; ELISA and western blotting were used to evaluate B. subtilis -Cap induced PCV2-specific IgA and IgG levels, as well as the secretion of cytokines and the expression of Toll-like receptor 2 (TLR2) and Toll-like receptor 9 (TLR9). Results We evaluated the immune response to B. subtilis -Cap in vitro using mouse BM-DCs and in vivo using neonatal piglets orally inoculated with B. subtilis -Cap. Our results showed that the recombinant B. subtilis -Cap activated BM-DCs, significantly increased co-stimulatory molecules (CD40 and CD80) and major histocompatibility complex II, and induced allogenic T cells proliferation. Piglets immunized with B. subtilis -Cap had elevated levels of PCV2-specific IgA in the mucosal tissues of the digestive and respiratory tract, and PCV2-specific IgG in serum ( P < 0.05 or P < 0.01). Ileal immunocompetent cells, such as the IgA-secreting cells ( P < 0.01), intestinal intraepithelial lymphocytes (IELs) ( P < 0.01), CD3 + T lymphocytes ( P < 0.01) and CD4 + T lymphocytes ( P < 0.01) increased significantly in the B. subtilis -Cap immunized piglets. Additionally, B. subtilis -Cap inoculation resulted in increased the expression of TLR2 and TLR9 ( P < 0.01), and induced the secretion of cytokines IL-1β, IL-6, interferon-γ, and β-defensin 2 ( P < 0.01). Conclusions We constructed a prototype PCV2 vaccine that can be administered orally and elicits a more robust humoral and cellular immunity than inactivated PCV2. B. subtilis -Cap is a promising vaccine candidate that is safe, convenient, and inexpensive. Further in vivo research is needed to determine its full range of efficacy in pigs. Graphical abstract

Cellular immune responses of piglets immunized with different dosage of PRRSV ORF5 gene vaccine by intramuscular injection

Thymidylate synthase polymorphism in Mexican patients with colon cancer treated with 5-fluorouracil.

Effects of Specific IgY Antibodies Against PRRSV and PCV-2-Cap Protein on Growth Performance and Immunity of Weaning Piglets

Effect of Route of Inoculation on Innate and Adaptive Immune Responses to Porcine Epidemic Diarrhea Virus Infection in Suckling Pigs

A Recombinant Plasmid Co-Expressing Swine Ubiquitin and the GP5 Encoding-Gene of Porcine Reproductive and Respiratory Syndrome Virus Induces Protective Immunity in Piglets.

Immune response in piglets orally immunized with recombinant Bacillus subtilis expressing the capsid protein of porcine circovirus type 2

Development and Implementation of Nutrition Education on Dietary Diversification for Primary School Children

Assessment of the efficacy of two novel DNA vaccine formulations against highly pathogenic Porcine Reproductive and Respiratory Syndrome Virus

Immunological evaluation of recombination PRRSV GP3 and GP5 DNA vaccines in vivo

Immunogenicity of the highly pathogenic porcine reproductive and respiratory syndrome virus GP5 protein encoded by a synthetic ORF5 gene

Response of lymphocytes from pigs naturally infected with porcine respiratory disease complex at 3 different stages of development

Studies on porcine circovirus type 2 vaccination of 5-day-old piglets

An interferon inducing porcine reproductive and respiratory syndrome virus vaccine candidate elicits protection against challenge with the heterologous virulent type 2 strain VR-2385 in pigs

Enhancing immunogenicity and antiviral protection of inactivated porcine reproductive and respiratory syndrome virus vaccine in piglets

Immunization with a recombinant fusion of porcine reproductive and respiratory syndrome virus modified GP5 and ferritin elicits enhanced protective immunity in pigs

Efficacy of the Synergy Between Live-Attenuated and Inactivated PRRSV Vaccines Against a NADC30-Like Strain of Porcine Reproductive and Respiratory Syndrome Virus in 4-Week Piglets

Glycoprotein 5-Derived Peptides Induce a Protective T-Cell Response in Swine against the Porcine Reproductive and Respiratory Syndrome Virus

[Eukaryotic expression of GP5 and M protein of porcine reproductive and respiratory syndrome virus and immunogenicity evaluation]

A decoupled reference generation algorithm for harmonic, reactive power and current unbalance compensation in three-phase systems

Evaluation of a Recombinant Mouse X Pig Chimeric Anti-Porcine DEC205 Antibody Fused with Structural and Nonstructural Peptides of PRRS Virus

Porcine GPX1 enhances GP5-based DNA vaccination against porcine reproductive and respiratory syndrome virus